Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.
- The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.
- Anocca has built validated asset franchises against valuable cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the pipeline.
- Anocca will initiate its first clinical program in hard-to-treat solid tumour indications with TCR-T therapies across multiple KRAS mutation forms and patient segments.
- 1 TCR-T therapies: T cell receptor-engineered T cell therapies – a type of cell therapy that uses the natural targeting ability of T cells to identify and eradicate diseased cells like cancer.